Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enclomiphene in men with acquired hypogonadotropic hypogonadism
NCT02651688Phase 2Completed
- Sponsor
- Repros Therapeutics Inc.
- Start
- Jan 2016
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of enclomiphene in acquired hypogonadotropic hypogonadism (AHH) (3 arms), sponsored by Repros Therapeutics Inc. Primary endpoints: Lean Body Mass at 48 weeks, Body Strength (Chest Press Weight) at 48 weeks and 16 more. Started Jan 2016; status: completed.
02
Drugs
enclomiphene
03
Conditions
acquired hypogonadotropic hypogonadism (AHH)
Beyond the preview
Go deeper on NCT02651688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02651688.